Lawton C A, Won M, Pilepich M V, Asbell S O, Shipley W U, Hanks G E, Cox J D, Perez C A, Sause W T, Doggett S R
Medical College of Wisconsin, Department of Radiation Oncology, Milwaukee 53226.
Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935-9. doi: 10.1016/0360-3016(91)90732-j.
Significant late intestinal and urinary morbidity from external beam irradiation for adenocarcinoma of the prostate has been a constant concern of both the urologist and the radiation oncologist. We analyzed two large Radiation Therapy Oncology Group trials (7506 and 7706) using primary irradiation in the treatment of local or locoregional adenocarcinoma of the prostate to assess morbidity via the Radiation Therapy Oncology Group scoring scheme (grade 1-5). One thousand twenty patients were treated in total with a minimum follow-up of 7 years in the surviving patients. There was a 3.3% incidence of intestinal complications defined as grade 3 toxicity or more with .6% of patients experiencing bowel obstruction or perforation. Urinary complications defined as grade 3 toxicity or more were found in 7.7% of patients with only 0.5% experiencing morbidity that would require a major surgical intervention such as laparotomy, cystectomy, or prolonged hospitalization. Intestinal and urinary complications were evaluated in reference to several parameters that might have an impact on their incidence (i.e., previous laparotomy, stage of disease, hypertension, positive lymph nodes, previous transurethral resection, total dose, and energy of accelerator used). Only total dose (greater than 70 Gray) was found to have a significant impact on the incidence of the urinary complications. None of these factors had a significant impact on the incidence of intestinal complications. These data from two large multi-institutional trials represent a fair estimate of the actual incidence of major intestinal and urinary complications from external beam irradiation in the management of local and locoregional adenocarcinoma of the prostate. Since the incidence of these major complications remains very low, we believe that external beam irradiation remains an excellent alternative to radical prostatectomy in the management of these patients.
前列腺腺癌外照射放疗导致的严重晚期肠道和泌尿系统并发症一直是泌尿外科医生和放射肿瘤学家持续关注的问题。我们分析了两项大型放射治疗肿瘤学组试验(7506和7706),这些试验采用初次放疗治疗前列腺局部或局部区域腺癌,通过放射治疗肿瘤学组评分方案(1 - 5级)评估并发症情况。总共治疗了1200例患者,存活患者的最短随访时间为7年。肠道并发症发生率为3.3%,定义为3级及以上毒性反应,其中0.6%的患者出现肠梗阻或穿孔。泌尿系统并发症定义为3级及以上毒性反应,在7.7%的患者中发现,只有0.5%的患者出现需要进行剖腹手术、膀胱切除术或长期住院等重大手术干预的并发症。根据可能影响肠道和泌尿系统并发症发生率的几个参数(即既往剖腹手术、疾病分期、高血压、阳性淋巴结、既往经尿道前列腺切除术、总剂量以及所使用加速器的能量)对并发症进行了评估。仅发现总剂量(大于70戈瑞)对泌尿系统并发症的发生率有显著影响。这些因素均未对肠道并发症的发生率产生显著影响。这两项大型多机构试验的数据合理估计了前列腺局部和局部区域腺癌外照射放疗中主要肠道和泌尿系统并发症的实际发生率。由于这些主要并发症的发生率仍然非常低,我们认为在外照射放疗在这些患者的治疗中仍然是根治性前列腺切除术的一个极佳替代方案。